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BACKGROUND AND PURPOSE: Stroke is associated with an increased risk of dementia. To assist in the early identification 
of individuals at high risk of future dementia, numerous prediction models have been developed for use in the general 
population. However, it is not known whether such models also provide accurate predictions among stroke patients. 
Therefore, the aim of this study was to determine whether existing dementia risk prediction models that were developed 
for use in the general population can also be applied to individuals with a history of stroke to predict poststroke dementia 
with equivalent predictive validity.
METHODS: Data were harmonized from 4 stroke studies (follow-up range, ≈12–18 months poststroke) from Hong Kong, the 
United States, the Netherlands, and France. Regression analysis was used to test 3 risk prediction models: the Cardiovascular 
Risk Factors, Aging and Dementia score, the Australian National University Alzheimer Disease Risk Index, and the Brief 
Dementia Screening Indicator. Model performance or discrimination accuracy was assessed using the C statistic or area 
under the curve. Calibration was tested using the Grønnesby and Borgan and the goodness-of-fit tests.
RESULTS: The predictive accuracy of the models varied but was generally low compared with the original development cohorts, 
with the Australian National University Alzheimer Disease Risk Index (C-statistic, 0.66) and the Brief Dementia Screening 
Indicator (C-statistic, 0.61) both performing better than the Cardiovascular Risk Factors, Aging and Dementia score (area 
under the curve, 0.53).
CONCLUSIONS: Dementia risk prediction models developed for the general population do not perform well in individuals with 
stroke. Their poor performance could have been due to the need for additional or different predictors related to stroke and 
vascular risk factors or methodological differences across studies (eg, length of follow-up, age distribution). Future work is 
needed to develop simple and cost-effective risk prediction models specific to poststroke dementia.
Key Words: aging ◼ dementia ◼ follow-up studies ◼ risk prediction ◼ risk factors
Cognitive impairment is common after stroke,
1 but 
stroke is also a strong independent risk factor for 
all-cause dementia.2 Approximately 10% of patients 
develop dementia soon after a first stroke, and more 
than a third have dementia after a recurrent stroke.3 The 
incidence of dementia after stroke is ≈50× higher in 
the year after a major stroke compared with the general 
population.4 Increasing numbers of patients are surviv-
ing a stroke, and this will lead to increasing numbers of 
patients later developing dementia. Reliable identification 
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of those at high risk could lead to improved risk factor 
management, better anticipation of care needs, and an 
increased opportunity to benefit from interventions to 
reduce dementia risk,5 including lifestyle-based interven-
tions recently emphasized by the World Health Organiza-
tion to delay or prevent cognitive decline and dementia.6
Poststroke dementia can be defined as any form of 
dementia that develops following a clinical cerebrovas-
cular event.7 Systematic reviews have identified over 20 
different dementia risk prediction models, and they have 
been shown to differ in their predictive accuracy.8–10 How-
ever, few models have been developed in a clinical set-
ting and even fewer have been externally validated, and 
those that have been externally validated have had mixed 
results.9,11–14 This raises the question of the applicability 
of such models outside the settings in which they were 
developed. Within the context of stroke, only 1 model has 
been developed to predict poststroke dementia15 and 2 
models have been developed to predict poststroke cogni-
tive impairment.16,17 While their predictive accuracy was 
found to be acceptable, the utility of such models is ques-
tionable because they all include neuroimaging variables 
that are costly to obtain and not easily accessible, particu-
larly in research settings or primary care where the major-
ity of stroke patients are followed. In addition, a previous 
population-based cohort study found neuroimaging vari-
ables did not significantly improve dementia risk predic-
tion accuracy when added to a simple model incorporating 
sociodemographic, cognitive, health, lifestyle, functional, 
and genetic predictors.18 Within the context of stroke, it 
is unclear whether simple prediction models excluding 
neuroimaging variables may be sufficient. Further, it is 
unknown whether dementia risk prediction models devel-
oped for the whole population will also offer accurate pre-
dictions in individuals with stroke. Thus, the aim of this 
study was to assess whether simple models developed to 
predict incident dementia in the general population also 
offer accurate predictions in stroke patients, which would 
thus permit the use of a single model to predict dementia 
regardless of disease subgroup.
METHODS
Data Availability
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Dementia Risk Models Selected for Testing
Dementia risk prediction models were selected from previous 
systematic reviews.8–10 Four criteria were used to select mod-
els: (1) published predictive accuracy as measured using the 
C statistic or area under the curve was acceptable at ≥0.70; 
(2) the models incorporated variables that could be simply and 
easily collected in primary care and research settings (ie, mod-
els that included neuroimaging variables were not considered); 
(3) similar or near similar predictor variables were available in 
our dataset; and (4) the models included both nonmodifiable 
and modifiable risk factors to allow for possible future work 
focused on the development of risk reduction strategies. Based 
on these criteria, 3 models were selected: (1) the Australian 
National University Alzheimer Disease Risk Index (ANU-ADRI) 
common variables model,14,19 (2) the Cardiovascular Risk 
Factors, Aging and Dementia (CAIDE) score,20 and (3) the Brief 
Dementia Screening Indicator (BDSI).21 Full details of each 
model are included in Table 1. Whenever possible, we used the 
same variables that were included in the original models. When 
the stroke cohorts in our study did not have the same variable, 
substitute variables were used. Full details of how the variables 
in the models were mapped in each stroke cohort and any vari-
able substitutions that were made are provided in Table I in the 
Data Supplement.
Stroke Patient Sources
Individual participant data were obtained via the STROKOG 
(Stroke and Cognition Consortium)—an international consor-
tium of longitudinal poststroke studies from around the world 
(Table II in the Data Supplement).22 To maximize the sample 
size and the number of incident dementia cases to adequately 
test the models, we harmonized data from multiple cohorts 
in the STROKOG study. Four datasets were included in this 
analysis, but they did not all have a full set of the risk variables 
that we needed to test each model. Therefore, model testing 
is based on harmonization of different combinations of the 4 
selected datasets as outlined below.
CU-STRIDE (Hong Kong)
STRIDE (Chinese University of Hong Kong–Stroke Registry 
Investigating Cognitive Decline) is a large cohort study 
(n=1007; age range, 20–98)23 that enrolled patients consecu-
tively admitted to an acute stroke unit of a university-affiliated 
hospital due to either a stroke or transient ischemic attack (TIA), 
excluding patients with prestroke dementia. To exclude patients 
with dementia before the index event, neurologists inquired 
about the patient’s cognitive function before stroke.23 Baseline 
demographic and vascular risk factors were collected, and neu-
ropsychological assessments were performed 3 to 6 months 
after the index event. Participants were followed for 5 years. 
Psychologists administered the Clinical Dementia Rating scale, 
with patients suspected of having dementia being assigned a 
Clinical Dementia Rating of one point or more, and the diagno-
sis of dementia was confirmed according to the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, criteria.
EpiUSA (the United States)
Consecutive ischemic stroke patients ≥60 years of age (n=585) 
and admitted to the Columbia-Presbyterian Medical Center 
were recruited and followed annually for up to 10 years.24 Initial 
assessments (excluding dementia diagnosis) were conducted 
7 to 10 days after stroke. Neurologists specializing in stroke 
administered a structured neurological examination and docu-
mented any history of cerebrovascular disease and vascular 
risk factors. Three months and then annually after stroke, neu-
ropsychological and functional assessments were performed, 
and dementia was diagnosed based on the Diagnostic and 
Statistical Manual of Mental Disorders, Third Edition, Revised 
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criteria. Following the exclusion of those who were not eligible 
for this study (eg, those who had dementia at baseline), 262 
patients were included in the present analyses.
CASPER (the Netherlands)
The CASPER study (Cognition and Affect After Stroke: 
Prospective Evaluation of Risks) is a prospective cohort study 
(n=246; age range, 42–91) of hospital-based patients con-
secutively admitted with a stroke.25 Baseline assessments were 
performed 10 to 12 weeks poststroke, with follow-up assess-
ments at 6 and 12 months. Based on the Diagnostic Criteria for 
Vascular Cognitive Disorders: A VASCOG Statement,26 patients 
with a vascular cognitive disorder (VCD) were identified, with 
major VCD being synonymous with dementia. It should be 
noted that vascular disease is considered the dominant, if not 
the exclusive, pathology in VCD.
STROKDEM (France)
STROKDEM (Study of Factors Influencing Post-Stroke 
Dementia) is a 5-year observational multicenter hospital-
based prospective follow-up study of a stroke population 
(n=200; age range, 25–87) without dementia (https://www.
clinicaltrials.gov; unique identifier: NCT01330160). Baseline 
and follow-up (6, 12, 36, and 60 months) evaluations included 
detailed cognitive and functional assessment. The Clinical 
Dementia Rating was used as a measure of cognitive impair-
ment. Diagnosis of dementia was based on neurological and 
general clinical examinations and activities of daily living.
Incident Dementia
Dementia diagnoses, based on each study’s definition of 
dementia, were recorded ≈12 to 18 months poststroke for 
each cohort. Although some studies had longer follow-up, a 
common follow-up time was used across the cohorts.
Inclusion Criteria
Since we wanted to assess the predictors of incident dementia 
after stroke, we excluded patients with TIA from the analyses. 
Individuals with dementia at baseline were also excluded when 
that information was available. We then performed our analyses 
in 2 rounds. The first round included all patients regardless of 
a history of stroke or subsequent recurrent stroke or TIA as 
this would be a better reflection of a stroke sample in clinical 
practice. In the second round, to perform a sensitivity analysis, 
those with a history of stroke, TIA, or intracranial hemorrhage 
were excluded. This would enable us to determine whether 
the model performance would improve in a distinct subset of 
stroke patients. Those who had a recurrent stroke between 
the baseline assessment and a follow-up assessment were 
also excluded from this second round of analyses when that 
information was available. A sensitivity analysis was done to 
ascertain whether there was a difference between those with a 
single versus recurrent episodes of stroke.
Statistical Analyses
All analyses were performed using Stata, version 15/16. Risk 
scores were calculated for each patient based on the 3 mod-
els and then assessed in the combined cohort as predictors of 
incident dementia over 12 to 18 months of follow-up. The main 
evaluative measures of model performance and comparison 
were discrimination and calibration. Discrimination refers to the 
ability of the model to accurately identify in 2 patients the one 
with and the one without the desired outcome.27 Calibration 
refers to whether the observed outcomes and predictions 
agree.27 We used the analytic methods that were chosen in the 
original publications to assess model performance. For exam-
ple, logistic regression was used to assess the CAIDE score 
and Cox regression was used to assess the BDSI and ANU-
ADRI scores. Discrimination was measured using the C statistic 
(Cox regression) or area under the curve (logistic regression). 
Calibration or model goodness of fit was tested using the χ2 
statistic for the logistic regression model and the Grønnesby 
and Borgan test for the Cox models. We did a complete case 
analysis for each risk score, that is, we only included patients if 
they contained all the variables of the model. Sensitivity analy-
sis found some differences in the demographic characteristics 
(ie, age, sex, and educational status) between those individu-
als included and those individuals excluded from the analysis 
(Table III in the Data Supplement).
ETHICS
This study was approved by Newcastle University’s Fac-
ulty of Medical Sciences Ethical Committee. The work 
of STROKOG has ethical approval from the University 
Table 1. Description of Each Model Being Externally Validated
Model Variables Model Discrimination Performance Outcome Follow-Up Time
ANU-ADRI14,19 
(common variables 
model)
Age, sex, education, diabetes mellitus, smoking, 
and alcohol
C statistics: 
CVHS, 0.73 (95% CI, 0.71–0.76); 
MAP, 0.69 (95% CI, 0.65–0.73); 
KP, 0.67 (95% CI, 0.63–0.70)
Alzheimer 
Disease
CVHS: median, 6.0 y; 
MAP: mean, 3.5 (SD, 3.0) y; 
KP: mean, 6.0 (SD, 5.7) y
CAIDE20 Age, sex, education, hypertension, body mass 
index, cholesterol, and physical activity
Area under the curve:
 0.77 (95% CI, 0.71–0.83)
Dementia Mean, 20.9 (SD, 4.9) y
BDSI21 Age (65–79 y), education, stroke, diabetes 
mellitus, body mass index, requiring assistance 
with money or medications, and depressive 
symptoms
C statistics: 
CHS, 0.68 (95% CI, 0.65–0.72); 
FHS, 0.77 (95% CI, 0.73–0.82); 
HRS, 0.76 (95% CI, 0.74–0.77); 
SALSA, 0.78 (95% CI, 0.72–0.83)
Dementia CHS, 6 y; FHS, 6 y; HRS, 6 y; 
SALSA, 6 y
ANU-ADRI indicates Australian National University Alzheimer Disease Risk Index; BDSI, Brief Dementia Screening Indicator; CAIDE, Cardiovascular Risk Factors, 
Aging and Dementia; CHS, Cardiovascular Health Study; CVHS, Cardiovascular Health Cognition Study; FHS, Framingham Heart Study; HRS, Health and Retirement 
Study; KP, Kungsholmen Project; MAP, Rush Memory and Aging Project; and SALSA, Sacramento Area Latino Study on Aging.
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of New South Wales’ Human Research Ethics Executive. 
The CU-STRIDE study was approved by the Chinese 
University of Hong Kong–North Territories East Cluster 
Clinical Research Ethics Committee. EpiUSA (Epide-
miologic Study of the Risk of Dementia After Stroke) 
was approved by the Institutional Review Board of the 
Columbia-Presbyterian Medical Center. The CASPER 
study was approved by the Medical Ethics Committee of 
Maastricht University Medical Center. The data provided 
by each study team were anonymized, and, therefore, 
consent was not needed.
RESULTS
Demographics for the individual and harmonized cohorts 
are shown in Table 2. The total harmonized sample 
included 1285 stroke patients with a mean age of 68.0 
(SD, 10.8) years; 42.7% women. The mean follow-up 
was 364.3 days (SD, 52.9).
Missing Data
The proportions of missing data among the predictive 
variables included in each model were small to moder-
ate (range, 0%–20.7%). See Tables IV through VI in the 
Data Supplement for full details of the missing data. For 
the BDSI model, 282 of the 406 eligible participants had 
complete data to evaluate the model. For the ANU-ADRI 
model, 1065 of the 1115 eligible participants had com-
plete data to evaluate the model. For the CAIDE model, 
873 of the 1082 eligible participants had complete data 
to evaluate the model.
Brief Dementia Screening Indicator
Two cohorts (EpiUSA and CASPER) were used to cre-
ate the harmonized dataset for testing the BDSI model. 
An overview of the baseline variables is shown in Table 
IV in the Data Supplement. The sample included 282 
patients (mean age, 65.9 years), of whom 16 devel-
oped dementia (mean follow-up, 336.0; SD, 51.7 
days). The discriminative performance (C statistic) 
of the BDSI as mapped in the original development 
study and the harmonized dataset is shown in the 
Figure. Compared with the development cohort, the 
discrimination of the BDSI was low, with a wide CI (C 
statistic, 0.61 [95% CI, 0.42–0.79]). The model was 
well calibrated (χ2=1.26; P=0.26).
ANU-ADRI (Common Variables Model)
Three cohorts (EpiUSA, CASPER, and CU-STRIDE) 
were used to create the harmonized dataset for test-
ing the ANU-ADRI model. An overview of the baseline 
variables is shown in Table V in the Data Supplement. 
The sample included 1065 patients (mean age, 68.6 
years), of whom 53 developed incident dementia 
(mean follow-up, 362.4 days; SD, 54.2). The discrimi-
native performance of the ANU-ADRI as mapped in 
the original development study and the harmonized 
dataset is shown in the Figure. Predictive accuracy 
was low (C statistic, 0.66 [95% CI, 0.58–0.74]). Simi-
lar to the BDSI, the CIs were wide. The model was well 
calibrated (χ2, 1.34; P=0.25).
CAIDE Score
Three cohorts (EpiUSA, CU-STRIDE, STROKDEM) 
were used to create the harmonized dataset for testing 
the CAIDE score. An overview of the baseline variables 
is shown in Table VI in the Data Supplement. The sam-
ple included 873 patients (mean age, 67.6 years), of 
whom 43 developed incident dementia (mean follow-
up, 370.4 days; SD, 51.0). The discriminative perfor-
mance of the CAIDE score as mapped in the original 
development study and the harmonized dataset is 
shown in the Figure. The discriminative ability of the 
CAIDE score was poor for predicting incident dementia 
(area under the curve, 0.53 [95% CI, 0.44–0.63]). The 
model was well calibrated (χ2, 13.7; P=0.39).
Sensitivity Analysis
We also performed a sensitivity analysis based on 
patients who had had only a single stroke (Tables IV 
through VI in the Data Supplement; Figure). The discrimi-
native accuracy of these models was not significantly dif-
ferently compared with the total stroke cohorts, and all 
models were well calibrated (all P>0.05).
Table 2. Overview of Individual Stroke Cohorts and the Total Harmonized Cohort
CU-STRIDE CASPER EpiUSA STROKDEM Total Harmonized Sample
n 650 203 262 170 1285
Age, y; mean (SD) 68.8 (11.0) 66.4 (11.6) 70.3 (7.1) 63.8 (12.5) 68.0 (10.8)
Women, % 286 (44.0) 66 (32.5) 136 (51.9) 60 (35.3) 548 (42.7)
No. of incident dementia cases, % 20 (3.1) 3 (1.5) 33 (12.6) 10 (5.9) 66 (5.1)
Follow-up time, d; mean (SD) 388.2 (31.2) 371.7 (15.5) 289.6 (53.9) 379.0 (40.1) 364.3 (52.9)
CASPER indicates Cognition and Affect After Stroke: Prospective Evaluation of Risks; CU-STRIDE, Chinese University of Hong Kong–Stroke Registry Investigating 
Cognitive Decline; EpiUSA, Epidemiologic Study of the Risk of Dementia After Stroke; and STROKDEM, Study of Factors Influencing Post-Stroke Dementia.
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DISCUSSION
In this study, we used harmonized data from STROKOG 
to test whether 3 dementia risk prediction models devel-
oped for use in the general population would accurately 
predict the incidence of dementia after stroke. This 
would have important implications because the identifi-
cation of those at the greatest risk of dementia could 
allow interventions to be developed to delay its onset or 
even reduce its incidence. We tested existing risk models 
in the hope that a single model could be used regard-
less of comorbidities such as stroke, but predictive per-
formance at ≈12 to 18 months poststroke was low (ie, 
<0.70) and poorer than the performance of the original 
development studies.
Our study replicates previous external validation work 
showing poor prediction of dementia using the CAIDE 
score,12,14 extending this work for the first time to individu-
als with stroke. This is likely to be due, in part, to meth-
odologic differences between studies and is unsurprising 
considering the change in population and study duration. 
In the development study, the mean age of participants 
was 50.4 years (SD, 6.0 years) and follow-up was ≈20 
years. In contrast, our study sample was older (mean age, 
68.4 years) and follow-up time shorter. Previous external 
validation studies of the CAIDE score have also found 
poor transportability when it is tested in older popula-
tions14 but not when looking at midlife risk for which it was 
developed.12 Second, it is possible that other variables that 
are not included in the CAIDE score such as those that 
are related to stroke or other vascular risk factors such as 
diabetes mellitus may also influence dementia risk.
With regard to the BDSI model, while the age distribu-
tion was similar between our study and the original devel-
opment cohort, follow-up time differed (ie, 6 years in the 
development study versus ≈12–18 months in our study). 
Previous validation studies using general population-
based samples have found comparable predictive accu-
racy during 2 years of follow-up.13 The BDSI includes age 
(1 point per year above age 65, up to 79 years of age), 
education (9 points), stroke (6 points), type 2 diabetes 
mellitus (3 points), body mass index (8 points), functional 
performance (ie, requiring assistance with money or med-
ications, 10 points), and depressive symptoms or taking 
antidepressant medications (6 points). In the context of 
stroke, this points system may not accurately reflect the 
true impact of these risk variables, particularly with regard 
to diabetes mellitus, which has been shown to be associ-
ated with an increased risk of dementia4,28 but allocated 
a low number of points in the BDSI model. Future work 
could explore both recalibration of the model in stroke-
specific populations and also to test the importance of 
other variables that might be independently associated 
with dementia,28 which could enhance predictive validity 
such as myocardial infarction and hypertension that are 
not included in this model.
The ANU-ADRI incorporates a wide range of vari-
ables, including age, sex, education, diabetes mellitus, 
smoking, and alcohol in the common variables model14,19 
to predict Alzheimer disease. The extended model also 
includes other modifiable risk factors such as physical/
cognitive activity and social network/engagement.14 The 
ANU-ADRI model’s predictive ability was low and simi-
lar to the BDSI but better than the CAIDE score, and 
we found in our stroke cohort that it showed similar dis-
criminative accuracy to one of the development cohorts, 
although the C statistic representing the accuracy of pre-
diction in that development cohort was also below the 
acceptable range. This may be because the ANU-ADRI 
model is not a midlife risk model and the mean age in the 
original testing cohorts at baseline tended to be older.14 
However, this may also emphasize the importance of age 
as a risk factor, particularly given that previous studies 
did not find much difference between the risk prediction 
model and a model containing age alone.13
There has only been one model published for predict-
ing poststroke dementia (Table VII in the Data Supple-
ment).15 It includes age, occupation, number of strokes, 
Figure. Performance of each model in the harmonized dataset.
Red line is the mean of the original development cohort area under the curve or C statistic. ANU-ADRI indicates Australian National University 
Alzheimer Disease Risk Index; BDSI, Brief Dementia Screening Indicator; CAIDE, Cardiovascular Risk Factors, Aging and Dementia score; CHS, 
Cardiovascular Health Study; CVHS, Cardiovascular Health Cognition Study; FHS, Framingham Heart Study; HRS, Health and Retirement Study; 
KP, Kungsholmen Project; MAP, Rush Memory and Aging Project; and SALSA, Sacramento Area Latino Study on Aging.
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left carotid vascular territory stroke location, admission 
NIH Stroke Scale score, admission Mini-Mental State 
Examination score, and admission Function Indepen-
dence Measure motor score.15 The model correctly clas-
sified 93.4% of patients 3 months after stroke.15 We were 
not able to test this model due to a lack of key risk vari-
ables, including consistent magnetic resonance imaging 
findings, in our stroke cohort. Rather, for this study, we 
chose to externally validate general population-based 
dementia risk prediction models to determine whether 
a single dementia risk model could be applied. How-
ever, it is likely that acceptable predictive performance 
will require condition-specific data to be included. The 
identification of a single accurate model that had readily 
available variables would be of benefit to clinicians and 
researchers and could guide multidomain interventions.29 
Our findings do not support the use of these general 
population-based dementia risk prediction models, how-
ever, and instead suggest that efforts should be made to 
develop stroke-specific models.
Implications of Dementia Risk Prediction in 
Stroke
Overall, the results from our study suggest that dementia 
risk prediction scores developed in the general popula-
tion do not work well in patients with stroke. This sug-
gests that there are differences in risk factor profiles 
across disease groups. For instance, a stroke population 
is already at higher risk by virtue of the risk factors that 
led to the clinically evident cerebrovascular event. Some 
of these variables are already found in the dementia risk 
models we tested, so perhaps there is little remaining 
in these models to explain the additional heterogeneity 
in risk beyond the initial stroke event. Stroke-specific 
variables may be required for the development of new 
models in this population. They may include anatomic 
stroke location, type of stroke, and history of recurrent 
stroke, which have been found to be risk factors for post-
stroke dementia.7 Although neuroimaging variables have 
previously been found to add little to simple risk predic-
tion models in dementia, this was at a population level.18 
Neuroimaging variables such as white matter lesions, 
cerebral atrophy, and medial temporal lobe atrophy have 
been found to be risk factors for dementia after stroke 
and could be used along with stroke-specific variables in 
the development of stroke models.30 However, magnetic 
resonance imaging is not always possible and would 
have significant resource implications. Harmonization 
of stroke cohorts is both feasible and has the potential 
to be used in the development of future risk prediction 
models, but we need to ensure that there is uniformity in 
how we report individual variables.
Although many of the variables in existing models may 
already be optimized poststroke, earlier identification of 
those who may have a dementia illness ensures earlier 
access to appropriate care and provides information that 
some patients, families, and clinicians value for subse-
quent decisions. In the context of trials, it may be that 
specific (eg, multidomain) interventions could be used 
in those at higher risk of dementia to improve or even 
preserve cognitive function. This has certainly been the 
case in those risk stratified by the CAIDE model,29 and a 
similar approach could be trialed in stroke cohorts.
Strengths and Limitations
Our study has a number of strengths. We used harmo-
nized data from 4 stroke cohorts to increase sample size 
and, therefore, statistical power. Furthermore, given the 
range of available variables, we were able to test, for the 
first time, 3 different dementia risk prediction models in 
a stroke population. However, there are some limitations. 
First, some variables were modified because the specific 
data required for the risk models were not available (Table 
I in the Data Supplement). This could have reduced com-
parability between our study and the development stud-
ies. However, we did ensure that the substitutions were 
as close as possible to the original definitions. Second, 
although the predictive accuracy of the 3 models was 
clearly poor, the incident dementia rate across studies 
was generally low, leading to wide CIs. Third, the crite-
ria for the diagnosis of dementia varied across cohorts, 
in particular, one cohort (CASPER) used VCD criteria 
to assess dementia and not a clinical rating. This could 
mean that individuals could be classed as minor VCD 
after they were classified as major VCD at subsequent 
follow-ups. Our analysis was similar to previous studies’ 
approach to the harmonization of dementia diagnoses 
across different cohorts (eg, see the COSMIC [Cohort 
Studies of Memory in an International Consortium] col-
laboration31). Fourth, the original models were gener-
ally developed in primarily white populations, which was 
also true in our study. We did include one South-East 
Asian population in the harmonized cohort for 2 of 
the models, although we did not specifically study the 
effects of ethnicity on the performance of those mod-
els. Finally, we undertook a complete case analysis, and 
this might have led to a select study population thereby 
affecting generalizability of the results. However, our 
sample size was large.
Conclusions
The number of individuals at risk of poststroke dementia 
is increasing, but there is no validated condition-specific 
prediction tool. The dementia risk prediction models that 
we studied did not perform well in our stroke cohort, 
underlining the importance of developing a stroke-
specific model, which will likely require the inclusion of 
a broader range of variables that are related to stroke 
and vascular risk factors and careful attention to their 
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weightings. The next step is to use data from harmonized 
stroke cohorts to provide a large stroke-specific popu-
lation for undertaking dementia risk prediction model 
development and external validation that is specific to 
this important subsample of individuals. We can then 
consider whether simple scores can be useful as the ini-
tial step in clinical monitoring of cognitive decline. The 
final model should permit the early identification of those 
individuals at the greatest risk of poststroke demen-
tia and thus provide the opportunity for early targeted 
interventions.
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